Avid Bioservices Inc (CDMO)

[cjgaddy]

Re: cv19 (I don’t capitalize things I hate), I think that “most of the people that we're talking to” and “several opportunities” means at least 3. I don’t think you put those ways if it’s 2 (it’s def. not one!). I'd like to see what just one cv19 strike would do to $76-81 and margins and profitability for FY21.

6-30-20: Joe Pantginis (H.C. Wainwright), “...going back to the potential COVID contracts…”
RICK HANCOCK (Int. CEO): So the contracts we're looking at currently, exclusivity is not really a part of it. The main drivers to get something through proof of concept as quickly as possible and I think one of the things that makes Avid an attractive partner for these kinds of things is, while we don't have the largest scale, some of them are requiring very small doses or very small amounts of material per dose, but the fact that we could take something very rapidly from proof of concept to commercial production with our many years of commercial capability. Just my opinion, I think the strategy of most of the people that we're talking to, based on where they are getting their funding from, the goal is to identify something that works either as a vaccine or therapeutic and then make it as widely available as possible.
TIM COMPTON (COO): It's very much timeline driven and certainly the exclusivity in those types of legal agreements have not been engaged or discussed on. It's really about delivering and timeline to deliver.

6-30-20: Matt Hewitt (Craig-Hallum), ”but given these COVID opportunities, how quickly would you anticipate hearing back…”
TIM COMPTON (COO): ...every opportunity is different, every timeline is different, but we certainly anticipate hearing back from some of the opportunities that we have in the queue for COVID probably in the next - probably next 90 days, but there are several opportunities in various stages of the sales cycle.
https://tinyurl.com/y9zbgmos